218 related articles for article (PubMed ID: 18550829)
1. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
[TBL] [Abstract][Full Text] [Related]
2. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.
Janeway KA; Zhu MJ; Barretina J; Perez-Atayde A; Demetri GD; Fletcher JA
Int J Cancer; 2010 Dec; 127(11):2718-22. PubMed ID: 20162573
[TBL] [Abstract][Full Text] [Related]
3.
Machado I; Claramunt-Alonso R; Lavernia J; Romero I; Barrios M; Safont MJ; Santonja N; Navarro L; López-Guerrero JA; Llombart-Bosch A
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612518
[TBL] [Abstract][Full Text] [Related]
4. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.
Chen Y; Zhang R; Mi D; Wang Q; Huang T; Dong X; Zhang H; Xiao H; Shi S
Gastric Cancer; 2023 Jan; 26(1):26-43. PubMed ID: 35999321
[TBL] [Abstract][Full Text] [Related]
5. Genetic aberrations of gastrointestinal stromal tumors.
Yang J; Du X; Lazar AJ; Pollock R; Hunt K; Chen K; Hao X; Trent J; Zhang W
Cancer; 2008 Oct; 113(7):1532-43. PubMed ID: 18671247
[TBL] [Abstract][Full Text] [Related]
6. Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era.
Dermawan JK; Kelly C; Gao Z; Smith S; Jadeja B; Singer S; Tap WD; Chi P; Antonescu CR
Clin Cancer Res; 2023 Oct; 29(19):3974-3985. PubMed ID: 37477937
[TBL] [Abstract][Full Text] [Related]
7. Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors.
Sun M; Tong Y; Yuan W; Wang Y; Pu Y; Huang W; Lv B; Xu C; Jiang W; Luo R; Fang R; Tang S; Ren L; Wang J; Feng J; Sun C; Shen K; He F; Hou Y; Ding C
Gastroenterology; 2024 Mar; 166(3):450-465.e33. PubMed ID: 37995868
[TBL] [Abstract][Full Text] [Related]
8. Primordial germ cells and gastrointestinal stromal tumors respond distinctly to a cKit overactivating allele.
Chen L; Faire M; Kissner MD; Laird DJ
Hum Mol Genet; 2013 Jan; 22(2):313-27. PubMed ID: 23077213
[TBL] [Abstract][Full Text] [Related]
9. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
Roulleaux Dugage M; Jones RL; Trent J; Champiat S; Dumont S
Front Immunol; 2021; 12():715727. PubMed ID: 34489967
[TBL] [Abstract][Full Text] [Related]
10. Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling.
Zhang S; Zhang L; Zhang D; Guo Y; Gao Y; Jiang Z; Li S; Liu A; Cao X; Tian J; Zhao S; Yu Y; Yang W; Bai R; Huang L; Yan H; Zhao H; Sun J
Mol Carcinog; 2024 Apr; ():. PubMed ID: 38629424
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-128 acts as a suppressor in the progression of gastrointestinal stromal tumor by targeting B-lymphoma Mo-MLV insertion region 1.
Wu J; Wang C; Cui X; Liu L; Wang L; Wang J; Xue X; Dang T
Clin Transl Oncol; 2024 Feb; 26(2):363-374. PubMed ID: 38103120
[TBL] [Abstract][Full Text] [Related]
12.
Di Vito A; Mandrone M; Chiocchio I; Gorini F; Ravegnini G; Coschina E; Benuzzi E; Trincia S; Nozella AH; Aasen T; Sanna C; Morroni F; Hrelia P; Poli F; Angelini S
Plants (Basel); 2024 Apr; 13(9):. PubMed ID: 38732416
[TBL] [Abstract][Full Text] [Related]
13. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
von Mehren M; George S; Heinrich MC; Schuetze SM; Yap JT; Yu JQ; Abbott A; Litwin S; Crowley J; Belinsky M; Janeway KA; Hornick JL; Flieder DB; Chugh R; Rink L; Van den Abbeele AD
Clin Cancer Res; 2020 Apr; 26(8):1837-1845. PubMed ID: 31792037
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary
Boichuk S; Dunaev P; Skripova V; Galembikova A; Bikinieva F; Shagimardanova E; Gazizova G; Deviatiiarov R; Valeeva E; Mikheeva E; Vasilyeva M; Kopnin P; Strelnikov V; Kiyamova R
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001614
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase (FTase) Inhibitors Increase Inhibition of KIT Mutants by Imatinib.
Fan Z; Zhang L; Zhang S; Liu A; Li S; Cao X; Tian J; Zhao S; Sun J
Rep Biochem Mol Biol; 2023 Apr; 12(1):74-82. PubMed ID: 37724142
[TBL] [Abstract][Full Text] [Related]
16. Tensin2 Is a Novel Diagnostic Marker in GIST, Associated with Gastric Location and Non-Metastatic Tumors.
Salmikangas S; Böhling T; Merikoski N; Jagdeo J; Sampo M; Vesterinen T; Sihto H
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804982
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options.
Mancarella C; Morrione A; Scotlandi K
Cells; 2021 Aug; 10(8):. PubMed ID: 34440844
[TBL] [Abstract][Full Text] [Related]
18. A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor.
Zhang F; Altindis E; Kahn CR; DiMarchi RD; Gelfanov V
Mol Metab; 2021 Nov; 53():101316. PubMed ID: 34400347
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factors: Ligands, binding proteins, and receptors.
LeRoith D; Holly JMP; Forbes BE
Mol Metab; 2021 Oct; 52():101245. PubMed ID: 33962049
[TBL] [Abstract][Full Text] [Related]
20. Novel Regulators of the IGF System in Cancer.
Mancarella C; Morrione A; Scotlandi K
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33673232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
